Vivendy Therapeutics Company
Vivendy Therapeutics is a pharmaceutical company founded in 2006 that focuses on developing enzyme replacement therapy for the treatment of Morbus Morquio (MPS IVA), a rare lysosomal storage disease. They have developed a modified recombinant human N-acetylgalactosamine-6-sulfatase (rhGALNS) that improves enzyme activity and enhances the efficacy of the therapy significantly.
Connections
Funding Status:
Early Stage Venture
Headquarters:
Basel, Basel-Stadt, Switzerland
Founded Date:
2006
Investor Type:
N/A
Investment Stage:
N/A
Technology:
Prevention
Employee Number:
1-10
Number Of Exists:
N/A
Estimated Revenue:
approximately €9.0
Industry:
Regenerative medicine